P | Q | R

Product #


Product Name

Biochem/physiol Actions

Gene Symbol (ID)

Add to Cart

SML2454 Q151 ≥98% (HPLC) Q151 is an inhibitor of bacterial inosine 5′-monophosphate dehydrogenase 2 (IMPDH2) with an IC50 value of 18 nM. It does not inhibit human IMPDH
Q4990 QBP1 ≥95% (HPLC) QBP1 is an inhibitor of polyglutamine protein aggregation and cell death. QBP1 inhibits polyglutamine aggregation in COS-7 cells at a concentration of 25 μM, as shown by complete inhibition of thioredoxin-Q62 aggregation assayed by turbidity at 405 nm. QBP1 reduces cell death of these cells by 50% and increases median life span from 5.5-52 days in Drosophilla melanogaster that expresses the expanded polyglutamine; can be shortened to 8 amino acids (Trp-Ley-Trp-Trp-Pro-Gly-Ile-Phe) without the loss of ability to inhibit polyglutamine aggregation. Several inherited neurodegenerative diseases, Huntington′s dentatorubral pallidoluysian atrophy, spinobulbar muscular atrophy, and spinocerebellar ataxia are caused by the expanded CAG repeats in the coding region of the gene, leading to accumulation of polyglutamine.
SML0481 Qc1 ≥98% (HPLC) Qc1 is a reversible inhibitor of threonine dehydroxygenase (TDH). The IC50 value for inhibition of TDH by Qc1 is 500 nM, with no detectable inhibition of other dehydroxygenase enzymes at concentrations up to 10 mM. Qc1 induces arrest and autophagy of mouse ES cells with an EC50 of 3 mM.
SML0393 QNZ46 ≥98% (HPLC) QNZ46 is a noncompetitive inhibitor of GluN2C/D containing NMDA receptors. KD and IC50 values for binding and inhibition of GluN1/Glun2D receptors by QNZ46 are 4.9 and 3.9 μM, respectively. QNZ46 does not compete for binding of glutamate or glycine, but QNZ46 receptor binding requires the binding of glutamate to the GluN2 subunit.
Q1626 Quene 1-AM    
Q4951 Quercetin ≥95% (HPLC), solid Quercetin is a flavonoid with anticancer activity. Quercetin is a mitochondrial ATPase and phosphodiesterase inhibitor. It Inhibits PI3-kinase activity and slightly inhibits PIP kinase activity. Quercetin has antiproliferative effects on cancer cell lines, reduces cancer cell growth via type II estrogen receptors, and arrests human leukemic T cells in late G1 phase of the cell cycle. Quercetin may also inhibit fatty acid synthase activity.
Q3638 Quetiapine hemifumarate salt ≥98% (HPLC) Quetiapine hemifumarate is an atypical antipsychotic, a combined serotonin (5HT2) and dopamine (D2) receptor antagonist.
Quetiapine promotes oligodendrogenesis in vitro. It is used in treating depressive disorders.
human ... DRD2(1813), HTR2A(3356), HTR2C(3358)
Q3251 Quinacrine dihydrochloride ≥90% Non-selective MAO-A/B inhibitor.
Quinacrine has anthelmintic functionality and used in the female sterilization. It is used to treat systemic lupus erythematosus and rheumatic diseases. Apart from malaria, Quinacrine is effective for treating giardia and tapeworm infections. It inhibits nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in addition to monoamine oxidase inhibition.
human ... MAOA(4128), MAOB(4129)
Q2763 Quinalizarin ≥95% (HPLC) Quinalizarin is a potent (IC50 = 110 nM), ATP-competitive, and highly selective (IC50 >1μM against CK1 and 72 other kinases) casein Kinase II (CK2) inhibitor.
Q0632 Quinapril hydrochloride ≥98% (HPLC), solid Quinapril is a short-acting angiotensin converting enzyme (ACE) inhibitor.
human ... ACE(1636)
Q3625 Quinidine anhydrous Class IA antiarrhythmic; potassium channel blocker.
Quinidine, an isomer of quinine has potential side effects like proarrhythmia on usage. It prolongs cardiac potential and is sodium channel blocker. It is a potential antagonist for α1-adrenoceptors and contributes to hypotension. It inhibits cytochrome P450 2D6 and improves circulation and brain penetration of dementia drug, dextromethorphan. Quinidine-dextromethorphan combination may be useful in treating pseudobulbar affect (PBA).
human ... ABCB1(5243), CYP2D6(1565), CYP3A4(1576), KCNH1(3756), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
mouse ... Abcb1a(18671), Abcb1b(18669)
rat ... Cyp2d1(266684), Cyp2d2(25053), Cyp2d3(24303), Cyp2d4v1(171522)
Q0875 Quinidine sulfate salt dihydrate Class IA antiarrhythmic; potassium channel blocker.
Q1250 Quinine hemisulfate salt monohydrate synthetic, ≥90% (HPLC) Potassium channel blocker. Antimalarial, anticholinergic, antihypertensive, and hypoglycemic agent; alkaloid originally isolated from the Cinchona family of South American trees. Inhibits mitochondrial ATP-regulated potassium channel. Used to study the metabolism of biocrystalized heme, hemozoin, in malarial parasites and to study the toxicity of heme (FP)-complexes.
Quinine has analgesic property.
Q1125 Quinine hydrochloride dihydrate Potassium channel blocker
Quinine is widely used in the treatment of malaria. It possesses erythrocytic and gametocytocidal action against Plasmodium sp. It also serves as an analgesic drug. Upon administration, quinine is present mostly bound to α-1 acid glycoprotein in the body fluids. Quinine has the ability to cross the placenta and the blood brain barrier. It has a half-life of 11-18 hours. Tinnitus, hearing defects, nausea and headache are some of its side effects.
SML1704 Quininib ≥98% (HPLC) Quininib is a cell penetrant, potent and selective cysteinyl leukotriene receptor 1 and 2 (CysLT1-2) antagonist that potently inhibits angiogenesis in a range of cell and tissue systems. Quininib inhibits retinal revascularisation in OIR mice. Quininib is effective at inhibiting angiogenesis in the mouse oxygen-induced retinopathy model. Additionally quininib inhibits endothelin-converting enzyme-2 (ECE-2).
Q102 (−)-Quinpirole hydrochloride ≥98% (HPLC), solid The putative D2 dopamine receptor agonist quinpirole (LY 171,555) is the most widely used D2 agonist in in vivo and in vitro studies Active enantiomer of (±)-quinpirole. Quinpirole is a dopamine agonist with high affinity for the D2 and D3 dopamine receptor subtypes. Specific [3H]quinpirole binding in rat brain was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. Saturation analysis revealed high affinity binding characteristics (KD = 2.3 +/- 0.3 nM) which were confirmed by association-dissociation kinetics. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles. A variety of drugs, most notably monoamine oxidase inhibitors (MAOls), inhibit the binding of [3H]quinpirole, but not [3H]spiperone or [3H](-)N-n-Propylnorapomorphine, in rat striatal membranes by a mechanism that does not appear to involve the enzymatic activity of MAO. Clinically antidepressant MAOIs exhibited selectivity between sites labeled by [3H]quinpirole and [3H]spiperone as did a number of structurally related propargylamines and N-acylethylenediamine derivatives and other drugs such as debrisoquin and phenylbiguanide. The MAOIs clorgyline and Ro 41-1049 were the most potent. MAOIs interact with a novel binding site that is labeled by [3H]quinpirole or that modulates [3H]quinpirole binding. This site may be associated with D2-like dopamine receptors.
human ... DRD2(1813), DRD3(1814)
C002 (±)-Quinuclidinyl benzilate powder Nonselective muscarinic acetylcholine receptor antagonist.
Q1004 Quipazine maleate salt Non-selective serotonin receptor agonist.
human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363)
SML2634 QX77 ≥98% (HPLC) QX77 is a chaperone-mediated autophagy (CMA) activator derived from the atypical retinoid AR7 that activates CMA by antagonizing retinoic acid receptor-α (RARα) signaling. QX77 rescues defective trafficking & lysosomal localization of the CMA receptor LAMP2A in cystinotic Ctns-/- MEFs and CTNS-KO human proximal tubule cells (PTCs) by restoring Rab11 expression and Rab11-positive vesicles trafficking to the level seen in wild-type cells (20 μM, 48 hrs). CMA activation by QX77 treatment (20 μM, 5 days) also significantly reduces toxic α-synuclein (α-syn) accumulation in PD patients iPSCs-derived astrocytes with LRRK2 G2019S mutation.